Medgen Secures Tens of Millions in Series B to Boost Regenerative Medical Materials Innovation

Recently, Shenzhen Medgen Life Sciences Co., Ltd. (hereinafter referred to as "Medgen") completed a Series B financing round of tens of millions of RMB, led by Shenzhen New Industry Private Equity Fund Management Co., Ltd. (hereinafter referred to as "Shenzhen New Industry Private Equity"), with Jolmo participating as a follow-on investor. Changhai Capital served as the financial advisor for this round.

The proceeds from this round will be used for the research and development, production line upgrades, and market launch of a series of material products related to serious medical care and consumer healthcare, including hydroxyapatite, collagen, and decellularized extracellular matrix. With the support of this round of capital, Medgen will simultaneously accelerate technological innovation and the market launch of consumer healthcare products, while continuing to invest in and iteratively upgrade its independent innovation and industrial translation platform for regenerative medicine materials, thereby promoting the high-quality development of China's advanced biomedical materials industry.

Since its establishment, Medgen has consistently focused on the frontier fields of biomedical materials, regenerative engineering, and translational medicine. With three core technology platforms—"hydroxyapatite regenerative product translation," "biomedical collagen technology," and "decellularized extracellular matrix technology"—as its strategic pillars, the company has built a full-cycle closed-loop capability covering "material research and development, process translation, clinical registration, and industrial application."

Leveraging its solid technological foundation and regulatory submission capabilities, Medgen has achieved market access breakthroughs for multiple core products. Its injectable artificial bone and oral bone graft substitutes have obtained Class III medical device registration certificates from the National Medical Products Administration in China, as well as Class D certification in Vietnam. The platelet-rich plasma preparation device has obtained a Class III certificate from the National Medical Products Administration in China, along with Class B certification in Indonesia and Class C certification in Vietnam.

In terms of market strategy, Medgen will continue to deepen its domestic and international market presence. Domestically, the company will continue to promote serious medical applications while preparing for the launch of consumer healthcare products. Simultaneously, it will accelerate overseas market breakthroughs and pursue coordinated progress in both arenas.

Driven by the synergistic operation of its three core technology platforms—"hydroxyapatite regenerative product translation," "biomedical collagen technology," and "decellularized extracellular matrix technology"—Medgen has built a product portfolio covering multiple clinical scenarios, including orthopedics, sports medicine, dentistry, and medical aesthetics, continuously translating scientific innovation into clinical value.

In the fields of orthopedics and sports medicine, leveraging its hydroxyapatite and collagen technologies, the company has successfully launched the first prefilled injectable artificial bone in China, which significantly simplifies surgical procedures and enhances clinical convenience and safety. Meanwhile, its cartilage repair product under development is designed to address structural cartilage defects, filling a market gap and providing patients with articular cartilage defects a superior regenerative repair solution.

In the fields of medical aesthetics and soft tissue repair, the company integrates the three core technologies of collagen, hydroxyapatite, and decellularized extracellular matrix. Through the synergistic combination of these materials, each leveraging its unique properties, Medgen has developed a product matrix targeting different anatomical sites and various layers of anti-aging treatment, offering safer and more biocompatible facial rejuvenation solutions for individuals of different ages and with diverse needs.

Among these, the decellularized extracellular matrix, through its ACE technology, fully preserves the native three-dimensional structure and collagen fiber network of the extracellular matrix, exhibiting excellent biocompatibility and low immunogenicity. It is capable of mimicking the body's own tissue microenvironment, allowing cells to reconstruct organized tissue structures in their proper positions. Building on this technological advantage, the company is accelerating the regulatory registration and clinical development of decellularized extracellular matrix products. 

Currently, its medical aesthetic hydroxyapatite products, collagen products, and decellularized extracellular matrix products are in the registration process, with certification efforts progressing at an accelerated pace. Multiple material composite products with upgraded formulations are currently in clinical trials. Looking ahead, Medgen plans to maintain a launch cadence of two to three medical aesthetic products per year, continuously enriching its multi-scenario, multi-tier regenerative medical aesthetic product matrix and reinforcing the competitive moat of its facial rejuvenation solutions. In addition, the development of products such as oral barrier membranes aims to provide Chinese patients with more cost-effective treatment options.

The completion of this financing round marks strong recognition from the capital market for Medgen's technological pathway, product pipeline, and business model, while also injecting significant momentum into the company's continued efforts to empower the high-quality development of regenerative medicine. Looking ahead, Medgen will fully leverage the enablement of this capital to accelerate the clinical validation and global deployment of its core products, deepen collaborations across the upstream and downstream industrial chain, and continuously expand high-end manufacturing capacity in compliance with Good Manufacturing Practice standards, ultimately delivering safe, advanced, and accessible regenerative medical products to every individual in need.